Stock Mover of the Day: Is Trinity Biotech plc (ADR) a Sell? The Stock Declines Again

Stock Mover of the Day: Is Trinity Biotech plc (ADR) a Sell? The Stock Declines Again

The stock of Trinity Biotech plc (ADR) (NASDAQ:TRIB) is a huge mover today! About 6.59M shares traded hands or 10792.20% up from the average. Trinity Biotech plc (ADR) (NASDAQ:TRIB) has risen 30.55% since March 1, 2016 and is uptrending. It has outperformed by 21.31% the S&P500.
The move comes after 6 months negative chart setup for the $152.21 million company. It was reported on Oct, 4 by Barchart.com. We have $5.82 PT which if reached, will make NASDAQ:TRIB worth $15.22 million less.

Analysts await Trinity Biotech plc (ADR) (NASDAQ:TRIB) to report earnings on October, 27. They expect $0.05 earnings per share, down 50.00% or $0.05 from last year’s $0.1 per share. TRIB’s profit will be $1.18 million for 32.25 P/E if the $0.05 EPS becomes a reality. After $0.06 actual earnings per share reported by Trinity Biotech plc (ADR) for the previous quarter, Wall Street now forecasts -16.67% negative EPS growth.

Trinity Biotech plc (ADR) (NASDAQ:TRIB) Ratings Coverage

Out of 3 analysts covering Trinity Biotech (NASDAQ:TRIB), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Trinity Biotech has been the topic of 4 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The stock of Trinity Biotech plc (ADR) (NASDAQ:TRIB) earned “Outperform” rating by Raymond James on Thursday, September 3. The stock has “Buy” rating given by TH Capital on Wednesday, July 29. The stock of Trinity Biotech plc (ADR) (NASDAQ:TRIB) has “Hold” rating given on Friday, October 23 by Craig Hallum.

According to Zacks Investment Research, “Trinity Biotech plc, headquartered in Bray, the Republic of Ireland, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market worldwide. The company provides two haemostasis product lines, Biopool and Amax, comprising test kits and instrumentation used for the detection of blood disorders. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. The Company is also a provider of raw materials to the life sciences industry. It also engages in the provision of engineering, financial, and management services, as well as in trading business. Trinity Biotech sells its products through its sales force, as well as through a network of distributors and strategic partners.”

More notable recent Trinity Biotech plc (ADR) (NASDAQ:TRIB) news were published by: Benzinga.com which released: “Trinity Biotech Plummets 50%: Here’s What You Need To Know” on October 04, 2016, also Benzinga.com with their article: “12 Biggest Mid-Day Losers For Tuesday” published on October 04, 2016, Barrons.com published: “Trinity Biotech PLC ADR” on August 31, 2015. More interesting news about Trinity Biotech plc (ADR) (NASDAQ:TRIB) were released by: Marketwatch.com and their article: “/quotes/zigman/3870025/realtime” published on July 07, 2009 as well as Quotes.Wsj.com‘s news article titled: “DOW JONES, A NEWS CORP COMPANY” with publication date: February 11, 2011.

TRIB Company Profile

Trinity Biotech plc (Trinity Biotech), incorporated on January 22, 1992, develops, acquires, makes and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) divisions of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two divisions: the Americas and Rest of World. Trinity Biotech is a well-known provider of raw materials to the life sciences and research industries around the world. Trinity Biotech markets its portfolio of approximately 850 products to clients in approximately 100 countries around the world, through its sales force and a network of international distributors and strategic partners. The primary market for Trinity Biotech’s diagnostic products is the Americas, which consists of North America and South America. Trinity Biotech also sells raw materials to the life sciences industry and research institutes around the world, through its subsidiary, Benen Trading Ltd., trading as Fitzgerald Industries. Trinity Biotech sells its products through its direct sales organizations in the United States, Brazil and the United Kingdom, and through a network of principal distributors and non-governmental bodies into approximately 100 countries around the world. The Company’s products are classified as POC, emergency medicine, clinical laboratory and blood bank screening.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment